Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenapanor T50 Trial in Hemodialysis Patients
jRCTs051250061Active, not recruiting
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tenapanor in chronic kidney disease (CKD) and hyperphosphatemia (4 arms). Primary endpoint: Change in T50. Started Jul 2025; status: active, not recruiting.
02
Drugs
tenapanor
03
Conditions
chronic kidney disease (CKD)hyperphosphatemia
Beyond the preview
Go deeper on jRCTs051250061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250061.